India is preparing for a major biotechnology expansion under the India Bioeconomy Roadmap 2035, with NITI Aayog outlining a strategy to scale the country's bioeconomy to $691 billion by 2035 while strengthening domestic capabilities across healthcare, biopharmaceuticals, diagnostics and advanced biotechnology.
The roadmap has potentially far-reaching implications for India's healthcare self-reliance. By expanding domestic research, biomanufacturing, innovation infrastructure and biotechnology companies, India could reduce dependence on imported technologies while becoming a larger global supplier of affordable healthcare solutions.
NITI Aayog's long-term ambition extends beyond 2035, with India's bioeconomy projected to potentially reach $2.6 trillion by 2047.
What Is India's Bioeconomy Roadmap 2035?
The India Bioeconomy Roadmap 2035 is NITI Aayog's ten-year strategy to position India among the world's leading biotechnology and bioeconomy powers.
It proposes moving from fragmented programmes toward coordinated, mission-driven initiatives covering strategic areas including healthcare, agriculture, industrial biotechnology, energy and environmental sustainability.
India's bioeconomy has already expanded dramatically.
It grew from approximately $10 billion in 2014 to $195.3 billion in 2025, representing roughly 4.8% of the country's GDP.
The next target is considerably more ambitious:
- 2025 bioeconomy: $195.3 billion
- 2035 target: $691 billion
- 2047 potential: $2.6 trillion
- Potential high-value jobs: More than 30 million
- Strategic ambition: Position India among the world's leading biotechnology powers
- Proposed BioEconomy Growth Fund: Rs 50,000 crore
The roadmap therefore goes beyond increasing biotechnology revenues. It seeks to build the research, manufacturing, talent, regulatory and investment ecosystem required for India to compete globally.
Why Is the India Bioeconomy Roadmap Important for Healthcare?
Healthcare could be one of the biggest beneficiaries of India's bioeconomy expansion.
Biotechnology already plays an essential role in the development and manufacturing of vaccines, biologics, biosimilars, diagnostics and other medical technologies.
Expanding India's capabilities in these areas could reduce dependence on imported products and technologies while strengthening the resilience of domestic healthcare supply chains.
The opportunity extends across:
- Vaccines
- Biopharmaceuticals
- Biosimilars
- Diagnostics
- Genomics
- Precision medicine
- Medical biotechnology
- Cell and gene therapies
- Synthetic biology
- Bioinformatics
- Disease surveillance
- Advanced biomanufacturing
For India, this creates both a healthcare opportunity and an economic opportunity.
A stronger domestic biotechnology industry could improve access to healthcare technologies while simultaneously positioning Indian companies as suppliers to international markets.
Six BioMissions Could Drive India's Biotechnology Strategy
A major proposal in NITI Aayog's roadmap is the creation of six mission-driven national initiatives, or BioMissions.
The objective is to replace fragmented biotechnology programmes with larger initiatives focused on clearly defined national priorities.
This mission-based model is intended to bring together research institutions, government agencies, startups, manufacturers and investors.
For healthcare, this could accelerate the journey from laboratory research to commercial products.
That transition remains one of the most difficult stages of biotechnology development because promising research requires substantial funding, clinical validation, regulatory approvals, manufacturing capacity and market access before it reaches patients.
Mission-mode programmes could help address these gaps by creating clearer pathways from discovery to deployment.
Rs 50,000 Crore BioEconomy Growth Fund Proposed
Financing is another major pillar of the roadmap.
NITI Aayog has proposed establishing a Rs 50,000 crore BioEconomy Growth Fund to support biotechnology innovation, infrastructure and commercialisation.
Biotechnology differs from many conventional startup sectors because product development can require long timelines and substantial capital.
Healthcare biotechnology is particularly demanding.
Developing new biologics, vaccines, diagnostics or advanced therapies may involve years of research followed by clinical testing, regulatory review and large-scale manufacturing investments.
Access to long-term capital is therefore essential.
A dedicated bioeconomy fund could potentially help Indian biotechnology companies cross the difficult gap between promising research and commercial-scale production.
Healthcare Self-Reliance Could Be a Major Outcome
One of the strongest strategic arguments for expanding India's bioeconomy is healthcare self-reliance.
The COVID-19 pandemic demonstrated how quickly disruptions in global supply chains can affect access to critical healthcare products and raw materials.
Countries subsequently increased their focus on domestic manufacturing capacity for vaccines, pharmaceuticals, medical technologies and critical health supplies.
India already has considerable pharmaceutical and vaccine manufacturing capabilities.
The next stage is to move further up the biotechnology value chain.
Instead of primarily manufacturing established products efficiently, India has an opportunity to increasingly develop original technologies, intellectual property and advanced biological platforms domestically.
From Generic Medicines to Advanced Biopharmaceuticals
India is globally recognised for its pharmaceutical manufacturing capabilities and its role in supplying affordable generic medicines.
Biotechnology creates an opportunity to extend that strength into more complex healthcare products.
These include:
- Monoclonal antibodies
- Recombinant proteins
- Advanced vaccines
- Biosimilars
- Cell therapies
- Gene therapies
- Genomic diagnostics
- Precision medicine technologies
- Next-generation biological platforms
These products typically require more sophisticated research and manufacturing capabilities than conventional small-molecule generic drugs.
Developing these capabilities domestically could therefore represent an important evolution of India's healthcare industry.
Biomanufacturing Could Become a Strategic Advantage
The roadmap also places substantial importance on biomanufacturing.
Biomanufacturing uses biological systems such as cells, microorganisms and enzymes to produce medicines, chemicals, materials, fuels and other products.
For healthcare, advanced biomanufacturing is critical for producing vaccines, biologics and other complex therapies at commercial scale.
India's advantage lies partly in its existing manufacturing base, large scientific workforce and comparatively competitive production costs.
If these strengths are combined with stronger research and intellectual property creation, India could emerge as a major global biomanufacturing destination.
BioE3 Policy Supports High-Performance Biomanufacturing
India's broader biotechnology ambitions are also supported by the government's BioE3 Policy — Biotechnology for Economy, Environment and Employment.
The policy focuses on promoting high-performance biomanufacturing while connecting biotechnology development with economic growth, employment and environmental sustainability.
This complements NITI Aayog's longer-term bioeconomy roadmap.
Together, these initiatives indicate a shift toward treating biotechnology not simply as a scientific sector but as strategic national infrastructure.
Diagnostics Could Benefit From Domestic Biotechnology
Diagnostics represents another major opportunity.
India has a large and diverse population, creating substantial demand for affordable diagnostic technologies across infectious diseases, cancer, cardiovascular conditions and other health challenges.
Domestic biotechnology capabilities could help expand access to:
- Molecular diagnostics
- Genomic testing
- Point-of-care diagnostics
- Rapid infectious-disease testing
- AI-assisted biological diagnostics
- Personalised medicine technologies
Reducing reliance on imported platforms and components could potentially lower costs while improving supply security.
Domestic innovation could also allow diagnostic products to be designed specifically for India's healthcare environment.
Genomics and Precision Medicine Could Expand
Genomics could become another major growth area under India's biotechnology expansion.
The falling cost of genetic sequencing has opened new opportunities for understanding disease risk, identifying genetic disorders and developing personalised treatment strategies.
India's enormous genetic diversity creates a particularly important opportunity for genomic research.
Building large-scale domestic genomic datasets and research infrastructure could support the development of healthcare solutions that better reflect Indian populations.
Over time, this could strengthen precision medicine, rare-disease research, cancer treatment and pharmacogenomics.
Disease Surveillance Could Become More Advanced
The roadmap also identifies biotechnology's role in strengthening disease surveillance.
Genomic sequencing and molecular surveillance became critical tools during the COVID-19 pandemic, helping governments identify emerging variants and understand disease transmission.
Expanding these capabilities could improve India's preparedness for future outbreaks.
An integrated biotechnology ecosystem could potentially allow authorities and researchers to:
- Detect emerging pathogens faster
- Sequence new variants
- Track disease transmission
- Develop diagnostic tests more rapidly
- Accelerate vaccine research
- Improve public-health responses
Healthcare self-reliance therefore involves not only manufacturing medicines but also developing the scientific infrastructure required to detect and respond to health threats.
India's Bioeconomy Has Grown Rapidly Since 2014
The scale of India's biotechnology transformation becomes clearer when viewed over the longer term.
India's bioeconomy was valued at approximately $10 billion in 2014.
By 2025, it had expanded to approximately $195.3 billion.
That represents roughly a 19-fold increase in value over little more than a decade.
NITI Aayog now believes the sector could more than triple again to reach $691 billion by 2035.
Achieving that target, however, will require growth not only in manufacturing but also in research, intellectual property, entrepreneurship and globally competitive biotechnology companies.
India Targets More Than 30 Million High-Value Jobs
The bioeconomy strategy also has major employment implications.
NITI Aayog estimates that the roadmap could support the creation of more than 30 million high-value jobs.
Employment opportunities could emerge across:
- Biotechnology research
- Biopharmaceutical manufacturing
- Healthcare
- Clinical research
- Bioinformatics
- Genomics
- Agriculture biotechnology
- Industrial biotechnology
- Environmental biotechnology
- Regulatory science
- Quality assurance
- Advanced manufacturing
Building the required workforce will require corresponding investment in universities, research institutions and specialised training.
Talent Will Be Critical to Reaching the $691 Billion Target
India already produces a large number of science, engineering and healthcare graduates.
However, advanced biotechnology requires specialised capabilities.
Researchers and companies increasingly need expertise spanning biology, chemistry, medicine, engineering, data science and artificial intelligence.
Emerging disciplines such as computational biology and synthetic biology combine several of these fields.
India will therefore need to strengthen the pipeline connecting education, academic research and industry.
The ability to retain high-quality scientific talent will also be important.
Regulation Could Determine How Quickly Innovation Reaches Patients
Funding and research alone will not determine the success of India's healthcare biotechnology ambitions.
Regulation will be equally important.
Healthcare biotechnology products can require extensive review because regulators must balance innovation with patient safety.
Predictable and science-based regulatory pathways could help companies plan investments and clinical development more effectively.
At the same time, faster approvals cannot come at the expense of safety or evidence standards.
The challenge is therefore to create regulatory systems that are both rigorous and efficient.
Indian Biotech Startups Could Gain New Opportunities
India's startup ecosystem could also benefit substantially from the bioeconomy push.
Biotechnology startups are emerging across areas including diagnostics, genomics, biological manufacturing, alternative proteins, agricultural biotechnology and healthcare technologies.
Unlike software startups, however, biotech companies often require laboratories, specialised equipment and longer development cycles.
This makes infrastructure and patient capital particularly important.
Shared research facilities, biofoundries, incubators and manufacturing infrastructure could reduce the cost of developing new products.
A stronger ecosystem could also help promising Indian research move from universities into commercial companies.
India Wants Globally Competitive Biotechnology Companies
NITI Aayog's roadmap is not focused solely on domestic demand.
A broader objective is to create Indian biotechnology companies capable of competing internationally.
The roadmap envisions establishing around 15 globally competitive biotechnology companies as part of India's transformation.
Achieving this would require Indian firms to build intellectual property, expand research capabilities and compete in advanced biotechnology markets rather than relying only on cost advantages.
Healthcare could be one of the strongest areas for this transition because India already has an established global pharmaceutical and vaccine presence.
Can India Become a Global Biotechnology Powerhouse?
India has several structural advantages.
The country combines a large scientific workforce, substantial domestic healthcare demand, established pharmaceutical manufacturing, a growing startup ecosystem and significant experience supplying medicines globally.
But reaching a $691 billion bioeconomy by 2035 will require coordinated execution.
Key requirements include:
- Greater investment in biotechnology R&D
- Long-term capital for biotech companies
- Stronger academia-industry collaboration
- Modern biomanufacturing infrastructure
- Faster but rigorous regulatory pathways
- Protection and commercialisation of intellectual property
- Advanced scientific workforce development
- Better technology transfer from laboratories to industry
- International research partnerships
- Predictable long-term government policy
The roadmap provides the strategic direction. Execution across these areas will determine whether its targets are achieved.
What Does the Bioeconomy Push Mean for Indian Healthcare?
For Indian healthcare, the significance of the bioeconomy strategy extends beyond the headline $691 billion target.
A successful biotechnology ecosystem could make India more capable of developing and manufacturing critical healthcare technologies domestically.
That could improve resilience against global supply disruptions while supporting more affordable healthcare products.
It could also shift India's position in the global healthcare industry.
India has already established itself as an important producer of pharmaceuticals and vaccines. The next opportunity is to become a larger creator of biotechnology platforms, intellectual property, advanced diagnostics and next-generation therapies.
In that sense, India's bioeconomy strategy is not simply an industrial growth programme.
It could become an important pillar of the country's long-term healthcare self-reliance.
0 Comments